The 340B drug discount program, designed to help vulnerable patients access affordable medications, has become a vehicle for hospitals and pharmaceutical companies to profit at the expense of the people it was meant to serve, critics say.
Created decades ago to ensure discounts reached low-income and underinsured patients, the program has instead evolved into a system where institutional gains often outweigh patient benefits. The disconnect between the program's original intent and its current operation has sparked calls for serious reform.
Hospitals and health systems have increasingly used 340B discounts to bolster institutional revenue rather than pass savings directly to patients. Meanwhile, states continue to fund and expand programs built on these same flawed mechanisms, inadvertently propping up a system that serves institutional interests more effectively than patient care.
The problems run deeper than misaligned incentives. Loopholes in the current structure allow manufacturers and middlemen to capture value that should reach those struggling to afford prescriptions. Without congressional action to close these gaps, the program will continue functioning as a profit mechanism for the wrong parties.
Experts and patient advocates argue that meaningful reform requires both state-level accountability and federal intervention. States should reassess their support for 340B-dependent programs, while Congress must act decisively to eliminate the regulatory gaps that enable the current system to persist.
Until those changes happen, a program that promised to democratize drug access remains a cautionary tale about how good intentions can be buried under institutional complexity and financial incentives.
Author James Rodriguez: "The 340B program proves that good intentions need good guardrails, and right now this program is missing both."
Comments